Nanocarriers for photodynamic therapy—rational formulation design and medium-scale manufacture  by Villa Nova, Mônica et al.
International Journal of Pharmaceutics 491 (2015) 250–260Pharmaceutical nanotechnology
Nanocarriers for photodynamic therapy—rational formulation design
and medium-scale manufacture
Mônica Villa Novaa, Christine Janasb, Mike Schmidtc, Thomas Ulshoeferc,
Susanna Gräfed, Susanne Schiffmannc, Natasja de Bruinc, Arno Wiehed,
Volker Albrechtd, Michael J. Parnhamc, Marcos Luciano Bruschia, Matthias G. Wackerc,*
a Laboratory of R&D of Drug Delivery Systems, Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, State University of Maringá, Av.
Colombo, 5790, Maringá, Paraná, Brazil
b Institute of Pharmaceutical Technology, Goethe University, 60438 Frankfurt (Main), Germany
c Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group for Translational Medicine & Pharmacology (TMP), 60596 Frankfurt/
Main, Germany
d biolitec research GmbH, Otto-Schott-Str. 15, 07745 Jena, Germany
A R T I C L E I N F O
Article history:
Received 2 April 2015
Received in revised form 8 June 2015
Accepted 14 June 2015
Available online 26 June 2015
Keywords:
Photodynamic therapy
mTHPC
PLGA–PEG
Microreactor technology
Experimental design
Photosensitizer
A B S T R A C T
The development and manufacture of novel nanocarriers for drug delivery has proved challenging with
regards to scale-up and pharmaceutical quality. Polymeric nanocarriers composed of poly(lactic-co-
glycolic acid)-b-poly(ethylene glycol) (PLGA–PEG) were prepared and the photosensitizer meso-tetrakis
(3-hydroxyphenyl) chlorin (mTHPC) was effectively encapsulated. Furthermore, the interplay of various
process and formulation parameters and their impact on the most important product speciﬁcations were
investigated by using a factorial design and a central composite design in a microﬂuidic manufacturing
process. These nanoparticles for intravenous administration with a size of 97  0.13 nm, narrow size
distribution, and an encapsulation efﬁciency of more than 80% were produced at high throughput. In vitro
stability and in vitro drug release testing were applied for quality control purposes. Finally, the toxicity of
the photosensitizer was tested in vitro. The cytotoxicity was successfully reduced while the efﬁcacy of the
formulation was maintained. First observations using in vivo imaging suggest effective distribution of the
nanocarrier system after injection into rodents. Thus, further in vivo testing of the beneﬁcial effects of
nanoencapsulation into the matrix system and its formulation will be considered for the delivery of
mTHPC to tumor tissues during photodynamic therapy.
ã 2015 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Pharmaceutics
journa l home page : www.e l sev ier .com/ loca te / i jpharm1. Introduction
Drug delivery has become one of the greatest challenges in
cancer therapy. By facilitating the selective accumulation of
compounds in tumor tissue, nanocarriers reduce the toxicity of
active pharmaceutical ingredients (API) while they maintain their
therapeutic efﬁcacy (Haley and Frenkel, 2008).
Photodynamic therapy (PDT) utilizes light-sensitive molecules,
so-called photosensitizers that are illuminated with visible or
infrared light. Once activated, these molecules generate singlet
oxygen, which causes the death of cancer cells and of the tumor* Corresponding author at: Fraunhofer Institute of Molecular Biology and Applied
Ecology (IME), Translational Medicine & Pharmacology (TMP), Department of
Pharmaceutical Technology and Nanosciences, Max-von-Laue-Str. 9, D-60438
Frankfurt (Main), Germany. Fax: +49 69 798 29694.
E-mail address: matthias.wacker@ime.fraunhofer.de (M.G. Wacker).
http://dx.doi.org/10.1016/j.ijpharm.2015.06.024
0378-5173/ã 2015 Elsevier B.V. All rights reserved.vasculature (Brown et al., 2004; Chen et al., 2010; Senge and
Brandt, 2011; Wacker et al., 2010).
Among photosensitizers, meso-tetrakis(3-hydroxyphenyl)
chlorin (mTHPC) is the only compound approved for clinical use
in the European Union, Norway, and Iceland for the palliative
treatment of patients with head and neck cancer who did not
respond to other therapies (Brown et al., 2004; Peng et al., 2014;
Senge and Brandt, 2011). Due to the high photodynamic activity of
the compound, only low doses of both the compound and light are
required (Sharman et al., 1999; Wacker et al., 2010).
Nevertheless, like most anti-tumor photosensitizers, mTHPC is
highly hydrophobic and consequently difﬁcult to administer
parenterally. Currently, an injectable formulation of the API is
marketed under the trademark Foscan1 and is composed of a
mixture of propylene glycol and anhydrous ethanol (European
Medicines Agency (EMA), 2013a). Due to the poor aqueous
solubility of the compound, mTHPC undergoes recrystallisation
after injection into the blood stream. Furthermore, the
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lard et al., 2007).
In this context, photosensitizer-loaded nanocarriers have the
potential to reduce side effects by modifying the physicochemical
properties and body distribution of the compound (Wacker et al.,
2010). Resomer1 is a family of well-deﬁned excipients that are
composed of poly(lactic-co-glycolic acid) (PLGA) and its deriva-
tives. These polymeric materials have been used previously in
parenteral drug formulations.
Since nanocarriers that have been surface modiﬁed with poly
(ethylene glycol) (PEG) demonstrate reduced uptake into macro-
phages of the reticuloendothelial system, PEGylation prolongs the
systemic circulation of nanoparticles and increases their accumu-
lation into tumors due to the resulting enhanced permeability and
retention (Avgoustakis et al., 2003; Beletsi et al., 2005; Chatterjee
et al., 2008; Kaul and Amiji, 2004; Kumari et al., 2010; Wacker,
2013). Therefore, PLGA–PEG nanoparticles have been used here for
drug delivery of mTHPC in mice. Earlier ﬁndings with nano-
particles consisting of the same material were undertaken using
lab-scale synthesis without any further optimization of the
colloidal carrier (Rojnik et al., 2012). Surprisingly, in this case
there was no difference in body distribution observed compared to
PLGA nanoparticles.
Formulation design is an essential step in the development of
new pharmaceutical products. Apart from toxicological and
pharmacological aspects, formulation composition, physicochem-
ical properties of the nanocarriers and the manufacturing process
play pivotal roles with regard to in vivo efﬁcacy and market
potential. In many cases, the scale-up of the established lab-scale
preparation methods is an obstacle to the production of drug
delivery devices and limits the number of nanotherapeutics on the
market (Wacker, 2013; Wacker, 2014). Moreover, only a few
procedures enable the large-scale production of nanoparticles
with appropriate process control to ensure manufacture within a
deﬁned speciﬁcation range (Pinto Reis et al., 2006).
The ‘scalability’ of nanoprecipitation methods is limited by
mixing and precipitation efﬁciency which may compromise the
particles properties (Karnik et al., 2008; Wacker et al., 2011).
Translation into a microreactor-based continuous ﬂow process
allows distinct control of relevant formulation parameters and
permits medium-scale production to provide the drug formulation
for pre-clinical to phase III studies (Karnik et al., 2008; Roberge
et al., 2009).
Accordingly, the present investigation focused on the optimi-
zation of the formulation design of mTHPC-loaded PLGA–PEG
nanoparticles in a microreactor-assisted nanoprecipitation setup.
A limited number of preformulation experiments and a Design of
Experiments (DoE) approach have been used.
A 24 factorial and a 22 central composite design were applied to
optimize the composition and to evaluate the effect of experimen-
tal parameters, including polymer concentration, stabilizer con-
centration, drug concentration, type of stabilizer, nitrogen gas
pressure, solvent-to-non-solvent ratio, and the ﬂow rate. The
optimized nanocarriers have been extensively characterized in
vitro. First in vivo studies have been conducted to investigate the
body distribution of mTHPC after nanoencapsulation into the
carrier matrix.
2. Materials and methods
2.1. Materials
The photosensitizer, meso-tetrakis(3-hydroxyphenyl) chlorin
(mTHPC), was kindly provided by biolitec research GmbH (Jena,
Germany). The block copolymer PLGA–PEG was composed of a
PLGA chain with an average molecular weight of 10,000 Da and aPEG chain with an average molecular weight of 5000 Da resulting
in a total molecular weight of 15 kDa and was kindly provided by
Boehringer Ingelheim (Ingelheim, Germany). It was identical in
composition to the commercially available PLGA–PEG derivatives
from the Resomer1 family (Evonik Industries, Germany).
Pluronic1 F-68, heat-inactivated fetal bovine serum (FBS),
b-methylcyclodextrin, and penicillin-streptomycin solution
(PenStrep1) were purchased from Sigma–Aldrich (Steinheim,
Germany); acetone and acetonitrile were purchased from Merck
KGaA (Darmstadt, Germany). Triﬂuoroacetic acid was purchased
from Alfa Aesar GmbH & Co KG (Karlsruhe, Germany).
The human colon adenocarcinoma cell line HT29 (DSMZ,
Braunschweig, Germany) and the mouse monocyte-macrophage
J774.A1 cell line (DSMZ, Braunschweig, Germany) were grown in
DMEM (PAA GmbH, Cölbe, Germany) supplemented with 10% heat-
inactivated fetal calf serum (FCS; PAA GmbH, Cölbe, Germany) and
1% (v/v) penicillin (10,000 IU) streptomycin (10,000 mg/mL, PAA
GmbH, Cölbe, Germany). Cells were kept as monolayer cultures in a
humidiﬁed incubator (5%, v/v) CO2 in air at 37 C. Cell culture was
re-seeded every week to ensure an exponential growth.
2.2. Preformulation studies
Since the number of experiments increases considerably with a
greater number of parameters that are included into the
experimental design, preformulation studies were conducted
and key parameters with a major impact on product characteristics
were identiﬁed. First experiments included the evaluation of
solvent-to-non-solvent (SNS) ratio, absolute ﬂow rate, and the type
of the stabilizing agent.
The impact of SNS ratio on precipitation efﬁciency was
investigated by mixing solutions of PLGA–PEG in acetone (5%,
w/v) and Pluronic1 F-68 (0.1%, w/v) at ratios of 1:1, 1:5, and 1:10.
These compositions were incubated in a Thermomixer (Eppendorf,
Hamburg, Germany) for 30 min, followed by centrifugation of the
suspension for 10 min at 20,800 rcf and microgravimetric analysis
of the supernatant. There were no signiﬁcant differences in the
amounts of non-precipitated polymer observed. Consequently,
PLGA–PEG nanoparticles were prepared at a deﬁned SNS ratio of
1:10 in the microreactor system (see Section 2.3). Absolute ﬂow
rates of 1.1, 2.2, 5.5 mL/min were adjusted and nanoparticles were
characterized with regard to particle size and polydispersity
index (PDI).
Finally, the type of the stabilizing agent was varied. Drug-
loaded nanoparticles were prepared at an absolute ﬂow rate of
2.2 mL/min and a SNS ratio of 1:10, utilizing Pluronic1 F-68 and
Pluronic1 F127 at concentrations of 0.1% and 1%.
2.3. Manufacture of nanocarrier formulations by microreactor-
assisted nanoprecipitation
The nanoparticles were prepared by microreactor-assisted
nanoprecipitation technology in a mixing chamber system (Ehrfeld
Mikrotechnik BTS GmbH, Wendelsheim, Germany) described
previously (Beyer et al., 2015). Brieﬂy, the reactor system was
composed of a central mixing chamber attached laterally to three
modules (see Fig. 1). Two inlet modules (right and left side) were
connected to L-6200HPLC pumps (Merck–Hitachi, Tokyo, Japan)
that controlled the ﬂow rates of organic polymer solution and
aqueous stabilizer solution. One inlet module (back side) was
connected to a nitrogen gas bottle. Both polymer and stabilizer
solutions were pumped into the microreactor chamber where
nanoprecipitation occurs. After formation of the nanoparticles in
situ, the product was forced out of the reactor under nitrogen
pressure. All process parameters were adjusted according to the
Fig. 1. Schematic illustration of the microreactor system.
252 M. Villa Nova et al. / International Journal of Pharmaceutics 491 (2015) 250–260experimental plan (see Section 2.4). No further puriﬁcation step
was undertaken prior to characterization.
2.4. Formulation development based on Design of Experiments
The experimental design was set up using the Statistica
8.0 software (StatSoft, Tulsa, OK). Initially, a full 4-factor, 2-level
factorial design was carried out to evaluate the effect of different
factors on the dependent variables, particle size, PDI, encapsula-
tion efﬁciency, and zeta potential. A center point was included into
the experimental plan to assess curvature of the model. The
independent variables for this design were nitrogen gas pressure
(X1), Pluronic1 F-68 concentration (X2), PLGA–PEG concentration
(X3), and mTHPC concentration (X4) (see Table 1). For the
prediction of the effects and interactions of all independent
variables, an analysis of variance (ANOVA) with a
p-value < 0.05 denoted statistical signiﬁcance of the effect at a
95% conﬁdence level.Table 1
Independent variable levels and results of % encapsulation efﬁciency (%EE), particle s
prepared using factorial design.
Independent variables Levels
Low (1) 
X1 = Nitrogen gas pressure (bar) 0.2 
X2 = Pluronic1 F-68 concentration (%) 0.1 
X3 = PLGA–PEG concentration (%) 1.0 
X4 = mTHPC concentration (mg/mL) 1.0 
Experiments X1 X2 X3 X4 %EE  SD 
1 0.2 1.0 1.0 1.0 43.46  4.46
2 0.5 1.0 1.0 1.0 39.22  3.90
3 0.2 0.1 1.0 1.0 61.42  0.64
4 0.5 0.1 1.0 1.0 56.50  1.30
5 0.2 1.0 5.0 1.0 75.00  0.91
6 0.5 1.0 5.0 1.0 74.10  3.07
7 0.2 0.1 5.0 1.0 88.55  0.17
8 0.5 0.1 5.0 1.0 88.28  0.12
9 0.2 1.0 1.0 2.0 40.72  0.21
10 0.5 1.0 1.0 2.0 36.15  3.51
11 0.2 0.1 1.0 2.0 66.71  1.24
12 0.5 0.1 1.0 2.0 64.14  0.52
13 0.2 1.0 5.0 2.0 73.14  1.18
14 0.5 1.0 5.0 2.0 72.73  0.26
15 0.2 0.1 5.0 2.0 85.63  0.47
16 0.5 0.1 5.0 2.0 87.30  1.25
17 [C] 0.35 0.55 3.0 1.5 55.37  0.59In a second step, a single formulation design was selected and a
2-factor, 5-level central composite design was implemented for
optimization of the ﬁnal formulation. In this case, independent
variables with the greatest impact on particle properties were
selected. These were polymer concentration (X1) and stabilizer
concentration (X2) (see Table 2).
2.5. Physicochemical characterization of nanocarrier formulations
The nanoparticles were characterized with regard to particle
diameter, PDI, and zeta potential. Therefore, a Zetasizer Nano ZS
(Malvern Instruments GmbH, Malvern, UK) was used. For
determination of particle content, microgravimetry was applied
(Mettler Toledo XP6U Ultra-microbalance, Gießen, Germany).
2.6. Determination of drug-loading efﬁciency
The drug-loaded nanoparticles were separated from non-
encapsulated drug by ultracentrifugation (Eppendorf 5430 R,
Hamburg, Germany) at 20,800 rcf for 10 min and the amount of
mTHPC loaded into the nanoparticles was calculated as the ratio of
the total drug amount and the amount that was recovered from the
supernatant.
Quantiﬁcation of mTHPC was undertaken using an HPLC
method, described previously (Beyer et al., 2015), after dilution
of the sample with mobile phase. The mobile phase consisted of
acetonitrile and 0.1% (v/v) triﬂuoroacetic acid solution (57.5:42.5,
m/m). A Gemini 5 mm NX-C18 reversed phase column (Phenom-
enex Inc., Aschaffenburg, Germany) was used as the stationary
phase. The samples were injected into a Hitachi Chromaster HPLC
system (Tokyo, Japan) equipped with a ﬂuorescence detector
(Model 5440), an auto sampler (Model 5260), a column oven
(Model 5310) and a pump (Model 5160). The ﬂow rate was adjusted
to 1.0 mL/min. An emission wavelength of 654 nm and an
excitation wavelength of 410 nm were used. The temperature
was kept constant at 30 C and the injection volume was adjusted
to 50 mL.ize, polydispersity index (PDI) and zeta potential of mTHPC-loaded nanoparticles
Central (0) High (+1)
0.35 0.5
0.55 1.0
3.0 5.0
1.5 2.0
Size (nm)  SD PDI  SD Zeta potential (mV)  SD
 75.33  1.06 0.083  0.004 18.73  1.77
 73.24  0.07 0.083  0.006 17.13  0.31
 71.00  0.41 0.066  0.009 21.10  1.65
 70.16  0.26 0.080  0.010 21.17  0.32
 102.37  0.35 0.076  0.013 17.33  0.47
 100.51  0.86 0.095  0.016 18.33  1.15
 110.80  0.30 0.073  0.004 19.73  0.87
 109.07  0.67 0.065  0.027 19.30  0.95
 74.26  0.20 0.076  0.013 12.63  0.32
 73.88  0.94 0.084  0.009 13.77  0.78
 80.17  0.77 0.066  0.028 9.94  0.79
 80.55  1.12 0.090  0.003 9.16  0.91
 101.90  0.87 0.079  0.012 15.87  1.93
 103.27  0.35 0.095  0.025 16.57  0.32
 109.83  0.90 0.054  0.030 16.13  1.04
 110.83  0.51 0.075  0.010 16.10  0.62
 81.53  0.78 0.060  0.012 19.63  1.18
Table 2
Independent variable levels and results of % encapsulation efﬁciency (%EE), particle size, polydispersity index (PDI) and zeta potential of mTHPC-loaded nanoparticles
prepared using central composite design.
Independent variables Levels Star points (a = 1.4142)
Low (1) Central (0) High (1) a +a
X1 = PLGA–PEG concentration (%) 3.6 5.0 6.4 3.0 7.0
X2 = Pluronic1 F-68 concentration (%) 0.071 0.100 0.129 0.041 0.141
Experiments X1 X2 %EE  SD Size (nm)  SD PDI  SD Zeta potential (mV)  SD Aggregation
1 3.6 0.071 79.06  0.61 83.54  0.25 0.070  0.015 17.70  1.38 
2 3.6 0.129 74.57  0.38 86.37  0.63 0.055  0.006 16.97  0.21 
3 6.4 0.071 85.99  0.32 108.90  0.40 0.093  0.014 18.96  0.31 +
4 6.4 0.129 83.61  0.59 112.43  0.68 0.101  0.016 18.20  0.27 +
5 3.0 0.100 75.44  0.69 83.78  0.29 0.076  0.008 19.10  0.70 +
6 7.0 0.100 91.55  0.15 161.00  0.60 0.115  0.011 14.00  0.35 +
7 5.0 0.041 86.06  0.19 94.96  0.12 0.078  0.016 18.97  1.15 +
8 5.0 0.141 81.52  0.50 99.10  0.48 0.082  0.020 18.37  0.15 
9 [C] 5.0 0.100 83.18  0.61 97.37  0.13 0.074  0.011 18.17  2.12 
10 [C] 5.0 0.100 82.61  0.42 97.23  0.05 0.074  0.012 18.20  0.20 
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scanning electron microscopy and transmission electron microscopy
The particle shape was examined by scanning electron
microscopy (SEM) and transmission electron microscopy (TEM).
For SEM analysis, an aliquot of 20 mL of the particle suspension was
placed on a sample holder and dried over 24 h. Thereafter, the
samples were coated with gold and analyzed with the scanning
electron microscope (Hitachi S4500, Tokyo, Japan).
The samples for TEM analysis were prepared by placing 20 mL of
nanoparticles suspensions onto a coated copper grid. After a drying
period of 1 h, the grids were immersed in an aqueous phospho-
tungstic acid solution (2%, w/v), washed twice in puriﬁed water
and dried for 24 h before analysis with the transmission electron
microscope (Philips CM 12, Amsterdam, Netherlands).
2.8. Characterization of nanocarrier formulations by light microscopy
The nanoparticle suspensions were dispersed in puriﬁed water
and examined for large aggregates by a Leica DMI 4000 B
microscope (Wetzlar, Germany) using 400-fold magniﬁcation. An
area corresponding to 10 mg of the formulation was examined.
2.9. Evaluation of cytotoxicity of nanocarrier formulations f15 and f9
A WST-1 assay system (Roche Diagnostic GmbH, Mannheim,
Germany) was used to determine the proliferation rate of
HT29 cells, which were seeded at a density of 1.5 104 and
treated for 24 h with mTHPC encapsulated in various nanoparticle
formulations. All preparations that contained photosensitizer were
used at drug concentrations of 0.1, 0.3, 2.5, 1.0, and 5.0 mg/mL. For
control preparations, the particle amount was adjusted to a value
that corresponded to the particle concentrations that were
achieved with the drug-loaded preparations. The drug formulation
Foscan1 was used as a reference.
After 24 h incubation, 10 mL of WST-1 reagent was added to
each well, mixed thoroughly, and incubated for 45 min at 37 C.
The absorbance of the dye was measured at 450 nm against a
reference wavelength of 620 nm using a 96-well spectrophoto-
metric plate reader (Enspire Plate Reader, Perkin Elmer, Waltham,
USA). The proliferation rate of untreated cells was used as an
index for 100% cell viability. The relative viability rate was then
expressed as the ratio of the cell viability of treated versus
untreated cells.2.10. In vitro stability of nanocarrier formulations f15 and f9
The in vitro stability of the colloidal system was assessed in a
medium that contained phosphate buffer saline (PBS) pH 7.4,
PenStrep1 (1%; v/v), b-methylcyclodextrin (1.0 mg/mL) and FBS at
concentrations of 0%, 10%, 50%, and 90%. The nanoparticle
suspension was mixed with the deﬁned medium and placed in a
thermomixer at 750 rpm and 37 C. Colloidal integrity was
measured by determination of particle size, PDI, and zeta potential
after a time period of 0 h, 4 h, 8 h and 24 h.
2.11. In vitro drug release of nanocarrier formulation f9
The in vitro release was determined using the dispersion
releaser technology described previously (Wacker and Janas,
2013). All experiments were conducted in a modiﬁed dialysis cell
for the USP dissolution apparatus II (DT 6R, Erweka, Germany). A
dialysis membrane of regenerated cellulose, MWCO 50 kDa
(Spectra/Por1 6, Serva Electrophoresis GmbH, Heidelberg,
Germany) was used and the medium was composed of PBS pH
7.4 supplemented with 50% FBS, 1% PenStrep1 and b-methyl-
cyclodextrin (1.0 mg/mL), which was used to ensure the dissolu-
tion of the drug over a period of 24 h. The colloidal formulation was
ﬁlled into the inner compartment of the dispersion releaser and
placed into vessels ﬁlled with an amount of 136 g of the release
medium incubated at 37 C. While continuously stirred at a rate of
75 rpm, aliquots of 0.5 mL were withdrawn from the outer
compartment at predetermined time points and replaced by fresh
medium.
For sample preparation, plasma proteins were precipitated with
0.1% (v/v) triﬂuoroacetic acid solution in acetonitrile. All samples
were centrifuged for 10 min at 20,800 rcf and a volume of 80 mL of
the supernatant was injected into the HPLC system and analyzed
by the method described above.
2.12. Evaluation of dark and phototoxicity of nanoparticle
formulation f9
The photosensitizer reference solution (2 mM in ethanol) was
kept in the dark at 4 C. Further dilution was performed in DMEM
medium without phenol red, supplemented with 10% FCS to adjust
ﬁnal photosensitizer concentrations of between 0.0 and 15 mM,
respectively. All nanoparticle formulations were diluted in the
same way as photosensitizer stock solution.
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were seeded into micro plates (2  103 cells/well). Cells were
incubated for 1 h before light exposure with fresh medium (DMEM
without phenol red) containing 10% FCS with the photosensitizer
or drug-loaded particle systems corresponding to the desired
photosensitizer concentration. Before photosensitization, cells
were washed, incubated with DMEM without phenol red and
10% FCS, and subsequently irradiated at room temperature with a
650 nm LED source (Omicron Laserage GmbH, Rodgau,
Germany) at a ﬁxed total light dose of 5 J/cm2, and at a ﬂuence
rate of 72 mW/cm2. Following irradiation, cells were incubated in a
humidiﬁed 5% CO2 incubator at 37 C for 24 h before applying the
cell viability assay. The cell viability was assessed using the XTTFig. 2. Contour plot of independent variables from factorial design for evaluation
the effect on particle size: (A) N2 pressure vs. polymer concentration; (B) polymer
concentration vs. stabilizer concentration; (C) polymer concentration vs. mTHPC
concentration.assay system. An amount of 500 mg XTT (Sodium 30-[phenyl-
aminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) ben-
zene sulfonic acid, Applichem GmbH, Darmstadt, Germany) was
dissolved in 500 mL PBS buffer (without Ca2+ and Mg2+) and sterile
ﬁltered. The solution was stored in the dark at 20 C until use.
A sterile solution containing PMS (N-methyl dibenzopyrazine
methyl sulphate, Applichem GmbH, Darmstadt, Germany) was
used as an activation reagent for the XTT. An amount of 0.383 mg
PMS was dissolved in 1 mL PBS buffer. The solution was stored
frozen and protected from light. The assay is based on the ability of
metabolically active cells to reduce the tetrazolium salt, XTT, to
orange-colored compounds of formazan. The dye formed is water
soluble and the dye intensity can be read at a given wavelength
with a spectrophotometer. The intensity of dye is proportional to
the number of metabolically active cells.
The XTT reagent solution was thawed in a 37 C water bath and
the activation solution (PMS) was added immediately prior to use.
To prepare a reaction solution sufﬁcient for one micro plate
(96 wells), 0.1 mL activation solution (PMS) was added to 5 mL XTT
reagent. The medium in the micro plate was replaced by fresh
DMEM without phenol red/10% FCS (100 mL) prior to adding 50 mL
XTT reaction solution per well. The microplate was incubated for
2–3 h at 37 C and 5% CO2. The absorbance of the samples was
measured with a spectrophotometer (Tecan Inﬁnite 200, Tecan
Group Ltd.) at a wavelength of 490 nm. In order to measure
reference absorbance (to measure non-speciﬁc readings), a
wavelength of 630–690 nm was used.
2.13. In vivo distribution studies of nanoparticle formulation f9 by
ﬂuorescence imaging with IVIS
A dose of 0.3 mg/kg of mTHPC was administered intravenously
into male CD-11 Crl:CD1(ICR) mice (obtained from Charles River,
8–10 weeks old) using two different formulations. One was
injected as the formulation Foscan1; another one as the
nanoparticle formulation f9. The animals were lightly anesthetized
with 2% isoﬂurane for ﬂuorescence imaging, following injection, in
the Xenogen IVIS 200 at 24 h with the following settings: excitation
ﬁlter, 430 nm; emission ﬁlter, 660 nm; ﬁeld of view (FOV) 22.5;
binning factor 8; 1 s exposure; f/stop 2.
2.14. Ethics
The procedures described were approved by the local Animal
Care and Use Committees and were in accordance with the
Principles of Laboratory Animal Care (NIH publication no. 86–23,
revised 1985). All efforts were made to minimize animal suffering,
to reduce the number of animals used, and to utilize alternatives to
in vivo techniques, if available.
2.15. Statistics
All data are expressed as means  standard deviation (SD). For
the determination of signiﬁcance, ANOVA was performed. Differ-
ences were considered to be signiﬁcant if p < 0.05. All experiments,
except in those in mice, were undertaken in triplicate.
3. Results and discussion
With the current approach, a rational formulation design was
applied to the synthesis and medium-scale production of nano-
carriers for targeted delivery of mTHPC. Initially, preformulation
studies were undertaken in order to reduce the number of factors
in the experimental design. DoE was used for the optimization of
formulation composition and process parameters. Finally, the
formulations were tested in vitro and in vivo.
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The elevated vapor pressure of organic solvents typically
impedes a controlled freeze drying process, which is necessary
to convert the aqueous suspension into a solid dosage form for
long-term storage (Seager et al., 1985). Since no differences in the
precipitation efﬁciencies have been observed at the different SNS
ratios, an initial SNS ratio of 1:10 was selected for the nano-
precipitation process. In this way, the amount of organic solvent in
the ﬁnal preparation could be minimized to enable the freeze
drying process.
In addition, the impact of the absolute ﬂow rates on particle
characteristics was monitored. At the highest ﬂow rate of 5.5 mL/
min, the PDI was considerably increased compared to that at the
lower ﬂow rates. Therefore, an absolute ﬂow rate of 2.2 mL/min
was selected to guarantee a high output and a constant product
quality.
Finally, the effect of the stabilizing agent on the drug
formulation was evaluated. There was no impact of this parameter
on particle size or PDI observed. However, the encapsulation
effciency decreased when Pluronic1 F127 was used (%EE 24–38%)
as stabilizing agent. Therefore, Pluronic1 F-68 (%EE 45–50%) was
selected for further experiments.
Accordingly, the independent variables, SNS ratio, absolute ﬂow
rate, and type of the stabilizer were excluded from the
experimental design by the preformulation studies.
3.2. Nanoparticle manufacture by microreactor-assisted
nanoprecipitation
Nanoprecipitation is a well-known technique for the prepara-
tion of nanoparticles on a lab-scale. The process is initiated by
controlled mixing of an organic polymer solution with an aqueous
stabilizer solution (Bilati et al., 2005). Once both solutions are in
contact, a spontaneous gradient-driven diffusion of the polymer
solution into the non-solvent occurs and leads to simultaneous
precipitation of the polymer and encapsulation of the drug (Chorny
et al., 2002; Fessi et al., 1989; Legrand et al., 2007).
On a large scale, nanoprecipitation is limited by inefﬁcient
mixing of liquids and poor reproducibility of the reaction
conditions (Zhang et al., 2013). The microﬂuidic platform applied
ensures rapid and effective homogenization and precipitation
which is crucial for the production of nanocarriers within a deﬁned
speciﬁcation range. Furthermore, the synthesis of nanoparticles inTable 3
ANOVA results of the factorial design related to the dependent variables particle size a
Source of variation Particle size 
SS Df MS F 
Curvature 224.37 1 224.37 484.58 
X1 = Nitrogen gas pressure 3.22 1 3.22 6.95 
X2 = Pluronic1 F-68 concentration 265.79 1 265.79 574.01 
X3 = = PLGA–PEG concentration 11717.2 1 11717.2 25305.5 
X4 = mTHPC concentration 92.55 1 92.55 199.87 
X1*X2 0.58 1 0.58 1.25 
X1*X3 0.54 1 0.54 1.16 
X1*X4 14.84 1 14.84 32.05 
X2*X3 140.12 1 140.12 302.61 
X2*X4 64.2 1 64.2 138.64 
X3*X4 48.18 1 48.18 104.05 
X1*X2*X3 0.94 1 0.94 2.03 
X1*X2*X4 0.18 1 0.18 0.39 
X1*X3*X4 1.71 1 1.71 3.70 
X2*X3*X4 86.59 1 86.59 187.01 
Error 16.21 35 0.46 
Total SS 12677.2 50 a continuous ﬂow process allows distinct control of the process
parameters and adaptation of the production output by ‘scaling
out’ procedures (Jahn et al., 2008; Legrand et al., 2007; Zhao et al.,
2011).
Nanoparticle formulations consisting of various inorganic (e.g.
magnetic, gold/silver), or organic (polymeric) materials have been
produced using different types of microreactors (Beyer et al., 2015).
Karnik et al. (2008) synthesized drug-loaded PLGA–PEG nano-
particles in a hydrodynamic ﬂow focusing microreactor and
veriﬁed that by varying ﬂow rates, polymer composition, and
concentration some important product characteristics such as
particle size, PDI, drug load, and release could be optimized.
Unfortunately, this microreactor did not permit the production of
larger amounts of colloids within a deﬁned speciﬁcation range. The
small diameter of the capillaries limited the capacity of the reactor.
Recently, manufacture of poly acrylate nanoparticles has been
optimized for medium-scale production in a three-channel
microreactor by our group (Beyer et al., 2015). The formulation
design was undertaken on a small-scale and important process
parameters were investigated.
In the present study, an optimized experimental design was
used to adjust the medium-scale manufacture and to systemati-
cally identify the most important independent variables of the
microreactor-assisted nanoprecipitation process (see Section 3.3)
allowing distinct control of therapeutically relevant product
characteristics. By adjusting optimal nitrogen pressure (see
Fig. 2) the liquid phase is rapidly removed from the chamber
resulting in a stable manufacturing process. By sterile ﬁltration of
polymer and stabilizer solution, microbial contamination of the
parenteral product can be avoided without further ﬁltration of the
particle suspension.
3.3. Formulation development based on DoE
3.3.1. Factorial design
The factorial design was implemented on 2 levels (low and high,
coded as 1 and +1, respectively), with 4 factors and one center
point (central, coded as 0). For optimization of the medium-scale
manufacturing process, a total number of 17 different experimen-
tal setups were tested. All experiments were undertaken in
triplicate.
Since a particle size between 50 and 250 nm is desirable for
parenteral drug delivery (Maeda et al., 2001) and particle size
inferior to 150 nm reduces phagocytic uptake (Fonseca et al., 2002;nd encapsulation efﬁciency
Encapsulation efﬁciency
p-value SS df MS F p-value
0.000 307.93 1 307.93 82.39 0.000
0.012 49.22 1 49.22 13.16 0.001
0.000 3887.52 1 3887.52 1040.15 0.000
0.000 10478.70 1 10478.70 2803.70 0.000
0.000 0 1 0 0 0.999
0.271 3.04 1 3.04 0.81 0.373
0.289 50.36 1 50.36 13.47 0.001
0.000 3.71 1 3.71 0.99 0.326
0.000 222.33 1 222.33 59.48 0.000
0.000 61.28 1 61.28 16.39 0.000
0.000 38.06 1 38.06 10.18 0.003
0.163 0.35 1 0.35 0.09 0.76
0.538 3.18 1 3.18 0.85 0.363
0.062 0.03 1 0.03 0.01 0.929
0.000 70.69 1 70.69 18.91 0.000
130.81 35 3.74
15307.2 50
Fig. 3. Contour plot of independent variables from factorial design for evaluation
the effect on eccapsulation efﬁciency: (A) polymer concentration vs. stabilizer
concentration; (B) N2 pressure vs. polymer concentration; (C) polymer concentra-
tion vs. mTHPC concentration.
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product speciﬁcation (in a range between 50 and 150 nm)
determining target site and circulation time in the blood stream.
The impact of different process parameters on particle size and the
interplay between those factors are illustrated by the following
regression equation:
Y ¼ 90:45  0:26X1  2:35X2 þ 15:62X3 þ 1:39X4 þ 0:56X1X4
 1:71X2X3  1:16X2X4  1:00X3X4 þ 1:34X2X3X4 (1)
From all experiments of the factorial design a mean particle size
of 90.45 nm was calculated. The coefﬁcients presented in Eq. (1)
represent the impact of various process parameters (X1–X4, see
Table 1) on particle size (Y), including 2- and 3-way interactions
between those factors (p < 0.05; see Table 3). For this dependent
variable a model ﬁt of 0.998 was achieved in the factorial design.
Among the independent variables, the greatest effect on
particle size was observed for X3 (polymer concentration), as
indicated by the coefﬁcient. An increase in polymer concentration
was accompanied by an increase in particle size by a factor of
+15.62. The impact of all independent variables on particle size is
illustrated in Fig. 2.
The nanoparticles were ranging in size between 70.2 and 110.8 nm.
Asexpected,particlesof largerdiameterswereobtainedwhenahigher
polymer concentration was used (see Table 1; e.g. formulations
5–8 and 13–16). The PDI values below 0.1 indicated narrow size
distribution. Thus, all tested formulations met the acceptance
criteriawith regard to particle size and size distributionparameters.
Characteristically for the polymer, a negative zeta potential was
observed (Danhier et al., 2009; Fonseca et al., 2002; Govender et al.,
1999). The absolute values ranged from 9.16 to 21.17 mV. A zeta
potential of more than 15 mV indicates physical stability of the
colloidal system (Riddick, 1968). Therefore, formulations
9–12 were excluded from further processing to assure high
stability of the particle system under in vitro and in vivo conditions.
Even more than the absolute drug load, encapsulation effciency
is a predictive marker for the release behavior of drug formula-
tions. The higher the afﬁnity of the compound to the polymeric
material, the lower the risk of a burst release in vivo (Wacker,
2013). Since all other acceptance criteria were met, formulations
were selected according to this parameter. The experimental setup
resulted in the following regression equation predicting the impact
of process parameters on encapsulation effciency:
Y ¼ 65:82  1:01X1  9:00X2 þ 14:78X3 þ 1:02X1X3
 2:15X2X3  1:13X2X4  0:89X3X4 þ 1:21X2X3X4 (2)
A mean encapsulation efﬁciency (Y) was calculated from all
experiments (65.82%). Similar to the investigations on particle size,
the coefﬁcients were calculated for all process parameters and
their interactions with a statistically signiﬁcant impact on
encapsulation effciency (p < 0.05; see Table 3).
The most pronounced effects were observed for variables X3
(polymer concentration) and X2 (stabilizer concentration), as
indicated by the coefﬁcients. The polymer concentration changed
the ﬁnal encapsulation efﬁciency by a factor of +14.78, the
stabilizer concentration by a factor of 9.00.
At elevated polymer concentrations, the absolute drug load
(and drug-to-polymer ratio) changed signiﬁcantly. By this,
additional binding sites were provided for the binding of drug
molecules (see Table 1,e.g. experiment 7).
For rising stabilizer concentrations, a ‘wash-out’ of the API was
observed (see Table 1, e.g. experiment 10). Under these conditions,
the drug was effectively solubilized by Pluronic1 F-68 and both
excipients competed for the small molecules.The impact of independent variables on encapsulation efﬁciency
is shown in Fig. 3. A model ﬁt of 0.991 was achieved. Encapsulation
efﬁciency ranged from 36.15  3.51% to 88.55  0.17%. The optimal
results were achieved for formulations 7, 8, 15 and 16 with values
greaterthan85%(seeTable1).All theseexperimentswerecarriedout
at a PLGA–PEG concentration of 5% (w/v) and a stabilizer
concentration of 0.1% (w/v). Among these formulation candidates,
formulation 15 (f15) contained the highest amount of mTHPC and
was prepared at low nitrogen pressure. Therefore, this formulation
was selected for further characterization.
Table 4
ANOVA results of the central composite design related to the encapsulation
efﬁciency.
Source of variation SS Df MS F p-value
X1 = PLGA–PEG concentration (L) 563.19 1 563.19 190.772 0.000
X1 (Q) 2.27 1 2.27 0.771 0.389
X2 = Pluronic F-68 concentration (L) 66.21 1 66.21 22.430 0.000
X2 (Q) 0.91 1 0.91 0.311 0.582
X1(L)*X2(L) 3.36 1 3.36 1.141 0.296
Error 70.85 24 2.95
Total SS 706.03 29
Note: (L): linear; (Q): quadratic.
Fig. 4. Contour plot of independent variables from central composite design for
evaluation the effect on encapsulation efﬁciency: polymer concentration vs.
stabilizer concentration.
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For further optimization of the formulation composition with a
focus on encapsulation efﬁciency, a central composite design was
implemented on 5 levels (low, central, and high coded as 1, 0 and
+1, respectively) including star points (a) (coded as 1.4142 and
+1.4142). In the factorial design PLGA–PEG and Pluronic1
F-68 concentrations had the greatest impact on encapsulation
efﬁciency, thus they were selected as independent variables for the
central composite design, with polymer concentration X1 and
stabilizer concentration X2. The following regression equation was
generated (p < 0.05; see Table 4):
Y ¼ 82:89 þ 4:84X1  1:66X2 (3)
By using the central composite design, an increase in the mean
encapsulation efﬁciency, from 65.82% (factorial design; see Eq. (2))
to 82.89% (central composite design; see Eq. (3)) was achieved,
suggesting an optimization of the preparation process compared to
the factorial design. PLGA–PEG is well-known for its poor drug
binding capacity and rapidly releases compounds after adminis-
tration. However, a high encapsulation efﬁciency of more than 80%
was achieved compared to other formulations known from the
literature, e.g. curcumin (%EE 73%) (Khalil et al., 2013), adriamycin
(%EE 25–33%) (Davaran et al., 2006), insulin (%EE 55%) (Ashjari
et al., 2012). In some studies encapsulation efﬁciency was not
quantiﬁed and complete entrapment (%EE 100%) of the API was
assumed (Peracchia et al., 1997; Rojnik et al., 2012).
For encapsulation efﬁciency, a coefﬁcient of determination of
0.900 was achieved in the central composite design. The impact of
PLGA–PEG and Pluronic1 F-68 concentration on encapsulation
efﬁciency is illustrated in Fig. 4. Initially, the dependent variables,
particle size and encapsulation efﬁciency, were monitored for the
DoE-based selection of formulation candidates. NanoparticlesFig. 5. SEM (upper) and TEM (lower) pwere synthesized ranging in size from 83.54 to 161 nm, with a
maximum PDI value of 0.115 and zeta potential between 14.0 and
19.1 mV (see Table 2). However, for many formulations evaluated
in the central composite design, the formation of large aggregates
was observed in the tubing of the microreactor system during the
preparation procedure. Such physical instability was observed
mainly with formulations exhibiting an unfavorable polymer-to-
stabilizer ratio.
Since these aggregates could not be determined in the DLS
measurements, the colloidal integrity was assessed by light
microscopic examination of the suspension prior to formulation
selection. Formulations that formed aggregates were excluded
from further processing (see Table 2).
Similar to f15 from the factorial design, formulation 9 (f9) from
the central composite design met all acceptance criteria with
regard to particle size (between 50 and 150 nm), size distribution
(PDI < 0.1), zeta potential (<15 mV), and encapsulation efﬁciency
(>80%). For f9 encapsulation efﬁciency was achieved at a moderate
polymer concentration assuring increased absolute drug load
compared to other formulations from the central composite
design. For only one formulation was an encapsulation efﬁciency of
more than 90% achieved (see Table 2, experiment 6). Compared to
this formulation the absolute drug load for f9 was increased
1.4-fold. Therefore, f9 was selected as the optimal candidate for
further evaluation.ictures of particle formulation f15.
Fig. 6. SEM (left) and TEM (right) picture of particle formulation f9.
Fig. 7. In vitro stability of photosensitizer-loaded PLGA–PEG nanoparticles (f9) in
phosphate buffer saline supplemented with 0% (A–D), 10% (E-H), 50% (I–L) and 90%
(M–P) of FBS after 0 h (black), 4 h (light grey), 8 h (dark grey), 24 h (grey),
means  SD, n = 3.
Fig. 8. Drug release of batch 1 (white dots) and batch 2 (black dots) of
photosensitizer-loaded PLGA–PEG nanoparticles (f9) determined with dispersion
releaser technology, means  SD, n = 3.
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The formulations f15 and f9 were examined by electron
microscopy. All particles had a spherical shape, as indicated by
TEM and SEM pictures (see Figs. 5 and 6) and lay within the
expected size range. No aggregates or drug crystals were observed.
This suggests a complete nanoencapsulation of the API into the
matrix material and a stable colloid system.
3.5. Evaluation of cytotoxicity of nanocarrier f15 and f9
The cytotoxicity of mTHPC-loaded PLGA–PEG nanoparticles
was investigated using the WST-1 cell viability assay system.
HT29 cells were exposed to increasing concentrations of mTHPC
and mTHPC-loaded nanoparticles under light exclusion. HT29 cells
that were treated with nanoparticles in the absence of the API
showed no change in cell viability. In contrast, after treatment with
Foscan1, the cells demonstrated a concentration-dependent
decrease in cell viability (data not shown). The cytotoxicity of
mTHPC was signiﬁcantly reduced by both nanoparticle formula-
tions. Comparing the formulations f15 and f9, similar %EE were
achieved. However, the decreased absolute drug load in f9 reduced
the cytotoxicity to values comparable to the blank nanoparticle
formulation and was selected as the optimal candidate for the
parenteral delivery system.
3.6. In vitro stability studies in serum
After administration into the human bloodstream, the surface
structure of nanoparticles is modiﬁed by adsorption or desorption
of proteins (Calatayud et al., 2014; Labarre et al., 2005; Sempf et al.,2013), aggregation, erosion, degradation, and metabolism. Since
these changes have a major impact on the biodistribution and
therapeutic efﬁcacy of nanocarriers, assessment of in vitro stability
in biological ﬂuids (e.g. in serum) has been included in the draft
guidance for development and approval of new nanocarrier
devices by the Food and Drug Administration of the United States
of America (Food and Drug Administration (FDA), 2002). Similar
regulations have been set up by other authorities due to the
increasing number of nanoformulations on the market (European
Medicines Agency (EMA), 2013b; Wacker, 2014).
The physical stability of our drug delivery system was assessed
by DLS. Intensity measurements with pure serum were used as a
control to assure a reliable determination of particle size and size
distribution. After an initial increase in the hydrodynamic
diameter (approximately 5 nm), the particle size was maintained
for 24 h in serum concentrations ranging between 0 and 90% (see
Fig. 7). Formulation f9 was sufﬁciently stable over the observed
time frame indicating optimal characteristics for in vivo applica-
tions.
3.7. In vitro drug release of nanocarrier formulation f9
For the in vitro release testing of nanoformulations, novel
dispersion releaser technology was used. In principle, the system
consists of an optimized dialysis chamber that is placed into a USP2
dissolution vessel (Wacker and Janas, 2013). The ﬂuids in the donor
Fig. 9. Evaluation of dark toxicity and phototoxicity of nanocarrier formulation f9 and mTHPC in ethanol in HT29 and J744A.1 cells, means  SD, n = 3.
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adjusted by using the USP2 dissolution apparatus. The formulation
was resuspended in release medium and ﬁlled into the inner
acceptor compartment.
Samples were taken from the outer compartment of the
dissolution chamber, as described above. The cumulative percent-
age release over a period of 24 h is illustrated for two different
batches of the nanoparticles in Fig. 8. This was equivalent to
86.7 4.7% for batch 1 or 75.7  2.8% for batch 2, respectively. For
both batches a constant but delayed release was observed,
suggesting a reproducible manufacturing process for both batches.
3.8. Evaluation of dark and phototoxicity of nanocarrier formulation f9
The dark and phototoxicity of f9, in comparison to that of
Foscan1, was assessed in vitro in HT29 and J774A.1 cells. For both
formulations, comparable phototoxicity was observed (see Fig. 9).
For the control, increasing dark toxicity was observed,
especially in J774A.1 cells at higher concentrations. In summary,
the efﬁcacy of the photosensitizer was maintained while the toxic
effects of the excipients were lower for the nanoparticle
formulation.Fig. 10. In vivo ﬂuorescence image 24 h after injection of Foscan1 (left) or
nanocarrier formulation f9 (right) (excitation wavelength 430 nm, emission
wavelength 660 nm).3.9. Examination of body distribution by in vivo imaging
The aim of the in vivo experiments was to monitor the body
distribution of mTHPC in mice after injection of Foscan1 or f9.
Unfortunately, the sensitivity of the ﬂuorescence measurement
was not sufﬁcient to detect mTHPC in deeper compartments of the
body. Similar observations have been made previously for nano-
carrier formulations of the compound (Rojnik et al., 2012). With
Foscan1, precipitation of the compound at the injection site (the
tail vein) and a delayed distribution were observed. No such signal
was seen with mTHPC-loaded nanoparticles (see Fig. 10). This
suggests improved distribution of the compound after injection.
Finally, more in vivo experiments will be necessary to provide
deeper insights into the effects of formulation parameters on body
distribution. Since ﬂuorescence intensity of the API was not
sufﬁcient for this purpose, labeling of the particles will be
necessary to follow the track of the nanocarrier system in deeper
compartments.
4. Conclusions
A rational formulation design was applied to the optimization
and the manufacture of mTHPC-loaded PLGA–PEG nanoparticles
and permitted the production of these nanocarriers at medium-
scale. The encapsulation efﬁciency was effectively controlled by
changing formulation parameters, including excipient composi-
tion and the conditions in the microreactor. An experimental
design was applied to evaluate the effect of each factor and resulted
in optimized nanocarriers. The particle size, PDI, and zeta potential
were within the speciﬁcation range that had been deﬁned for the
parenteral route of administration. No changes of these parameters
were observed in the presence of serum proteins, suggesting
physical stability of the formulation in biological environment.
Further, by encapsulation of mTHPC into the nanocarriers, the
cytotoxicity of the formulation was successfully reduced. A
constant release proﬁle revealed a high batch-to-batch reproduc-
ibility of the chosen manufacturing process and formulation
design.
The biodistribution of the compound was evaluated in vivo in
mice. Although the sensitivity of the ﬂuorescence imaging was not
sufﬁcient to monitor the body distribution, in contrast to the
marketed formulation, Foscan1, effective distribution of the
compound into the inner compartments was observed.
260 M. Villa Nova et al. / International Journal of Pharmaceutics 491 (2015) 250–260Thus, we conclude that the formulation developed by a scalable
continuous ﬂow process has the potential for the effective delivery
of mTHPC. Further in vivo testing will be conducted in order to
show the beneﬁcial effects of nanoencapsulation with regard to
biodistribution and therapeutic efﬁcacy.
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